Top 10 Companies in the Global Chitosan and Chitosan Derivatives Market (2026): Market Leaders Driving Sustainable Innovation

MARKET INSIGHTS

The Global Chitosan and Chitosan Derivatives Market was valued at USD 1.9 billion in 2024. The market is projected to grow from USD 2.1 billion in 2025 to USD 3.8 billion by 2032, exhibiting a CAGR of 9.5 % during the forecast period.

Chitosan and its derivatives are natural biopolymers derived primarily from chitin, a structural component found in crustacean shells. These versatile biomaterials are characterized by their biodegradability, biocompatibility, and non‑toxicity, making them suitable for a wide range of applications. Key chitosan derivatives include chitosan oligosaccharides, carboxymethyl chitosan, and chitosan hydrochloride, each offering unique functional properties tailored to specific industry needs.

The market is experiencing robust growth driven by increasing demand across pharmaceutical, food, cosmetic, and water treatment industries. Rising adoption in wound healing, drug delivery systems, and dietary supplements is a significant growth factor. Furthermore, advancements in production technologies and growing emphasis on sustainable, bio‑based materials are contributing to market expansion. Key players such as Primex, FMC Corporation, and Kitozyme are actively investing in R&D and strategic partnerships to enhance their product portfolios and market presence.

Global Chitosan and Chitosan Derivatives Market – View in Detailed Research Report

Top 10 Companies in the Global Chitosan and Chitosan Derivatives Market (2026)

1️⃣ Primex EHF

Headquarters: Reykjavik, Iceland
Key Offering: High‑purity chitosan for pharmaceutical and cosmetic applications

Primex has positioned itself as a benchmark for quality, leveraging Iceland’s clean energy infrastructure to drive low‑carbon production. Its portfolio includes a range of chitosan derivatives optimized for drug delivery and wound care, supported by a robust R&D pipeline focused on molecular weight tailoring.

Sustainability Initiatives: Utilisation of renewable electricity, closed‑loop water recycling, and partnership with local seafood processors to secure a steady supply of shellfish waste.

• Secured EU MDR compliance for medical‑grade chitosan in 2025.
• Launched a joint venture with a biotech university to explore chitosan‑based gene therapy vectors.
• Achieved a 15 % reduction in CO₂ emissions per kilogram of product in 2026.

2️⃣ FMC Corporation

Headquarters: St. Louis, USA
Key Offering: Broad portfolio of chitosan and derivatives for pharmaceutical, nutraceutical, and food applications

FMC’s Health & Nutrition division has expanded its footprint in the biopolymer space, integrating chitosan into its existing line of functional ingredients. The company’s advanced deacetylation processes yield high‑purity products that meet stringent pharmacopeia standards.

Sustainability Initiatives: Investment in enzymatic deacetylation to lower chemical usage, and a strategic partnership with a global seafood consortium to promote circularity.

• Introduced a plant‑based chitosan derivative in 2025, targeting the vegan nutraceutical market.
• Implemented a digital traceability system for raw‑material sourcing in 2026.
• Achieved ISO 14001 certification for its manufacturing facilities.

3️⃣ Novamatrix (FMC Health & Nutrition)

Headquarters: Oslo, Norway
Key Offering: Medical‑grade chitosan for wound dressings, drug delivery, and ophthalmology

Novamatrix leverages FMC’s global network to deliver high‑grade chitosan products to the medical sector. Its focus on stringent quality controls has earned approvals from the FDA and EMA for several drug‑delivery platforms.

Sustainability Initiatives: Utilisation of biobased feedstock and zero‑waste manufacturing processes.

• Launched a new chitosan‑based hydrogel for ocular drug delivery in 2025.
• Partnered with a European university to study chitosan’s antibacterial properties.
• Reduced water consumption by 12 % per ton of chitosan in 2026.

4️⃣ Kitozyme S.A.

Headquarters: Brussels, Belgium
Key Offering: Enzymatic chitosan production for pharmaceutical and cosmetic markets

Kitozyme’s patented enzymatic process delivers chitosan with controlled deacetylation, enabling precise tuning of viscosity and solubility for high‑value applications.

Sustainability Initiatives: Focus on renewable energy and zero‑emission production lines.

• Received CE marking for a chitosan‑based wound dressing in 2025.
• Collaborated with a Dutch research institute on bio‑fabrication of tissue scaffolds.
• Cut chemical usage by 20 % through process optimisation in 2026.

5️⃣ Heppe Medical Chitosan GmbH

Headquarters: Munich, Germany
Key Offering: Medical‑grade chitosan for wound care, hemostatic agents, and drug delivery

Heppe Medical has built a reputation on rigorous quality control and a strong regulatory portfolio, with several products approved by the German Federal Institute for Drugs and Medical Devices.

Sustainability Initiatives: Integration of circular supply chains and adoption of green chemistry principles.

• Introduced a chitosan‑based hemostatic spray in 2025.
• Partnered with a German university for clinical trials on chitosan‑enhanced bone grafts.
• Reduced energy consumption by 8 % in 2026.

6️⃣ Golden Shell Pharmaceutical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Food‑grade and pharmaceutical‑grade chitosan for drug delivery and food preservation

Golden Shell has scaled its production to meet the rising demand in Asia, focusing on cost‑effective purification technologies and compliance with Chinese GMP standards.

Sustainability Initiatives: Vertical integration from shellfish waste processing to high‑purity chitosan production, reducing raw‑material transport costs.

• Achieved GMP certification for a new chitosan line in 2025.
• Launched a joint venture with a local seafood company to secure raw‑material supply.
• Implemented a waste‑to‑energy program, generating 5 kWh per ton of chitosan produced.

7️⃣ Kunpoong Bio Co., Ltd.

Headquarters: Seoul, South Korea
Key Offering: Cosmetic‑grade chitosan for skincare and nutraceuticals

Kunpoong Bio has carved a niche in the premium personal‑care segment, leveraging Korean consumer demand for natural ingredients. Its products are widely distributed across East Asian beauty markets.

Sustainability Initiatives: Use of renewable energy and a closed‑loop production system.

• Released a chitosan‑based anti‑aging serum in 2025.
• Collaborated with a Korean university to study the antioxidant properties of chitosan oligosaccharides.
• Reduced packaging waste by 30 % through recyclable materials in 2026.

8️⃣ Advanced Biopolymers AS

Headquarters: Oslo, Norway
Key Offering: Industrial‑grade chitosan for chemical and environmental applications

Advanced Biopolymers focuses on large‑scale production of chitosan for use in wastewater treatment and as a bio‑flocculant in the chemical industry.

Sustainability Initiatives: Commitment to carbon neutrality and use of renewable feedstock.

• Introduced a chitosan‑based heavy‑metal removal system in 2025.
• Partnered with a Norwegian environmental agency to pilot large‑scale flocculation projects.
• Achieved a 10 % reduction in greenhouse gas emissions per ton of chitosan in 2026.

9️⃣ Qingdao Honghai Bio‑tech Co., Ltd.

Headquarters: Qingdao, China
Key Offering: Food‑grade chitosan for edible coatings and preservative applications

Qingdao Honghai has built a strong presence in the food sector, providing high‑purity chitosan that meets both Chinese and international food safety standards.

Sustainability Initiatives: Emphasis on local sourcing and waste minimisation.

• Secured ISO 22000 certification for its food‑grade products in 2025.
• Launched a community outreach program to educate local fishermen on sustainable shellfish waste management.
• Reduced chemical usage by 18 % in 2026.

🔟 Zhejiang New Fuda Ocean Biotech Co., Ltd.

Headquarters: Zhejiang, China
Key Offering: High‑purity chitosan for biomedical and cosmetic applications

Fuda Ocean Biotech has positioned itself as a key supplier in the Asia‑Pacific region, focusing on advanced purification techniques that deliver pharmaceutical‑grade chitosan.

Sustainability Initiatives: Adoption of green chemistry and a circular economy model.

• Introduced a chitosan‑based hydrogel for wound healing in 2025.
• Collaborated with a Chinese university on a clinical study of chitosan‑enhanced drug delivery.
• Achieved a 12 % reduction in waste generation per ton of chitosan in 2026.

Download FREE Sample Report

Get Full Report

Outlook

Between 2025 and 2034, the Global Chitosan and Chitosan Derivatives Market is expected to expand from USD 2.1 billion to USD 5.0 billion, driven by sustained demand in high‑value sectors such as pharmaceuticals, cosmetics, and advanced water treatment. The Asia‑Pacific region will remain the largest contributor, with China and Japan maintaining leadership in production and consumption. In North America and Europe, stricter environmental regulations and a push for bio‑based materials will continue to lift market activity, especially in the pharmaceutical and cosmetic arenas.

Future Trends

• Digitalisation of the supply chain, with blockchain traceability for raw‑material provenance.
• Emergence of non‑crustacean chitosan sources (fungi, insects, algae) to diversify supply and appeal to vegan markets.
• Integration of chitosan into additive manufacturing and 3‑D bioprinting for tissue engineering.
• Expansion into agricultural applications, such as seed coatings and biopesticides, to capture the growing sustainable farming market.
• Continued investment in enzymatic and fermentation‑based production to lower carbon footprints and improve product consistency.